FDA-approved1,2Evidence: Limited human dataHeart and blood vessels

Vasopressin1

Also called Vasostrict1,2

Key takeaway

Vasopressin is a peptide hormone that narrows blood vessels and helps the kidneys hold on to water. Vasostrict is a synthetic version of arginine vasopressin.1 FDA approved Vasostrict in 2014 to raise blood pressure in adults with vasodilatory shock whose blood pressure stays low despite fluids and catecholamine drugs.1,2 The label’s summary of its human evidence is brief: blood pressure rose in seven studies in septic shock and eight after heart surgery, with no further detail on study design.1

Vasopressin at a glance

What it isA synthetic polypeptide hormone, arginine vasopressin, that acts on V1 receptors in blood vessels and V2 receptors in the kidney, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Vasostrict with an original approval date of April 17, 2014. The cited label has no boxed warning.1,2
Human evidenceStudies in septic shock and in shock after heart surgery, summarized in one sentence in the label without sample sizes or design details.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is vasopressin?

Vasopressin is a polypeptide hormone. Vasostrict is a sterile solution of synthetic arginine vasopressin, according to the label.1

In the United States, Drugs@FDA lists it as Vasostrict, approved under NDA 204485.2

How does vasopressin work?

The label states that vasopressin narrows blood vessels by binding V1 receptors on vascular smooth muscle, and causes the kidneys to retain water by stimulating V2 receptors.1

What do human studies show?

The label states that increases in systolic and mean blood pressure were observed in seven studies in septic shock and eight in vasodilatory shock after heart surgery.1

The label does not report the size or design of these studies, or effects on survival.1

What the evidence base contains

  • Small, short, or incompletely reported human study Seven studies in septic shock and eight in vasodilatory shock after heart surgery, in which systolic and mean blood pressure rose, summarized in the label without design or size.1

Evidence-strength label: Limited human data. How this label is assigned

Is vasopressin FDA-approved?

Yes. Drugs@FDA lists Vasostrict, application NDA 204485, with an original approval date of April 17, 2014.2

The Vasostrict label cited here (DailyMed SPL version 49, published May 18, 2026) states that it is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.1

The label has no boxed warning. Its warnings state that it can worsen heart function and that reversible diabetes insipidus can follow when treatment stops.1

Timeline

  1. FDA approves Vasostrict, according to Drugs@FDA.2
  2. DailyMed publishes the Vasostrict label version cited on this page.1

What is still unknown?

Whether raising blood pressure with it improves survival: the label’s clinical studies section reports blood pressure effects only.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Vasopressin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Vasopressin are a bounded selection, not every registration or paper about Vasopressin. For the years before Vasopressin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Vasopressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Vasopressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Vasostrict for vasodilatory shock. The label summarizes studies in septic shock and after heart surgery in which blood pressure rose, without reporting their size or design.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Vasopressin?

FDA-approved as Vasostrict for vasodilatory shock. The label summarizes studies in septic shock and after heart surgery in which blood pressure rose, without reporting their size or design.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
17
Drugs@FDA applications
14

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗Source date November 5, 2026
  2. Literature metadata · added November 15, 2026

    International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).↗Source date November 1, 2026
  3. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT05958342↗Source date October 30, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Vasopressin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

83Selected dated records
85Connected citations
17Populated source years1998–2026
3/4Record lanes present

Registered human studies

Trial composition

30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 2 9Phase 3 9Phase 4 9Not applicable 4Phase 1 3
Status at observationCompleted 21Recruiting 4Active, not recruiting 3Enrolling by invitation 1Not yet recruiting 1

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Review 28Case Reports 4Research Support, Non-U.S. Gov't 3Consensus Statement 1English Abstract 1Multicenter Study 1Randomized Controlled Trial 1Research Support, N.I.H., Extramural 1Research Support, U.S. Gov't, Non-P.H.S. 1Systematic Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
14
FDA Federal Register documents
9
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
83

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 83 dated records

Research hub

Explore the Vasopressin evidence record

Open all 83 records →
83Dated records
3Evidence types
83Cited public sources
17Source years

Change ledger

Recently changed for Vasopressin

Open all 83 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00269685

PeptideScanner retained ClinicalTrials.gov record NCT00269685 at 2026-11-15T22:08:31.832Z. Its registry update date was 2006-05-29, and PeptideScanner's reviewed identity mapping was vasopressin.

PeptideScanner change date
November 15, 2026
Cited source date
May 29, 2006
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00358579

PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.

PeptideScanner change date
November 15, 2026
Cited source date
March 17, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00379522

PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.

PeptideScanner change date
November 15, 2026
Cited source date
November 5, 2014
Evidence lane
Clinical trials

Official-source collections

Source records for Vasopressin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Arginine vasopressin deficiency: towards a better characterization.Endocrine-related cancer · 2026 Sep 01
  2. From cranial diabetes insipidus to vasopressin deficiency: terminology, tests and treatment.Archives of disease in childhood · 2026 08 19
  3. Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review.International journal of molecular sciences · 2026 08 16
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05958342Registry update October 30, 2026 · current at observation
  2. NCT04501861Registry update October 27, 2026 · completed at observation
  3. NCT07633600Registry update October 22, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA14

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA212068Full FDA chronology · original submission status AP 2026-05-06
  2. ANDA212069Full FDA chronology · original submission status AP 2026-05-06
  3. NDA217766Full FDA chronology · original submission status AP 2024-07-11
  4. ANDA213988Full FDA chronology · original submission status AP 2024-05-08
  5. ANDA216963Full FDA chronology · original submission status AP 2024-02-09
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Vasopressin →

Evidence types

Coverage by source year

Selected records span September 25, 1998 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 83

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗

    PubMed lists PMID 41862144 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).↗

    PubMed lists PMID 39438674 in Nature reviews. Nephrology as Journal Article, Review, Consensus Statement, with publication-date metadata of 2024-10-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05958342↗

    PeptideScanner retained ClinicalTrials.gov record NCT05958342 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04501861↗

    PeptideScanner retained ClinicalTrials.gov record NCT04501861 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07633600↗

    PeptideScanner retained ClinicalTrials.gov record NCT07633600 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  6. Literature metadata

    Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants.↗

    PubMed lists PMID 40602377 in Hormone research in paediatrics as Journal Article, Review, with publication-date metadata of 2025-07-02 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    A Scoping Review on Salivary Oxytocin and Vasopressin Measurement in the Dog.↗

    PubMed lists PMID 40867749 in Animals : an open access journal from MDPI as Journal Article, Review, with publication-date metadata of 2025-08-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Arginine vasopressin deficiency: towards a better characterization.↗

    PubMed lists PMID 42677919 in Endocrine-related cancer as Journal Article, Review, with publication-date metadata of 2026-09-01 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    The vasopressin system as an immunoneuroendocrine therapeutic target in inflammatory conditions.↗

    PubMed lists PMID 42647984 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-08-10 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT06709573↗

    PeptideScanner retained ClinicalTrials.gov record NCT06709573 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  11. Literature metadata

    From cranial diabetes insipidus to vasopressin deficiency: terminology, tests and treatment.↗

    PubMed lists PMID 41667271 in Archives of disease in childhood as Journal Article, Review, Case Reports, with publication-date metadata of 2026-08-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review.↗

    PubMed lists PMID 42653310 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-08-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    VASOSTRICT (vasopressin) injection · SPL version 49 · published 2026-05-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: VASOSTRICT (vasopressin), NDA 204485 · original approval April 17, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026